311 related articles for article (PubMed ID: 29380516)
1. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
[TBL] [Abstract][Full Text] [Related]
2. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA
Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390
[No Abstract] [Full Text] [Related]
3. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
4. Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.
Tsakonas G; Grozman V; Ekman S
Clin Lung Cancer; 2020 Nov; 21(6):e544-e546. PubMed ID: 32522509
[No Abstract] [Full Text] [Related]
5. Dabrafenib and trametinib in BRAFV600E mutated glioma.
Brown NF; Carter T; Kitchen N; Mulholland P
CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
[TBL] [Abstract][Full Text] [Related]
6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
8. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
9. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
11. Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
Yau WH; Ameratunga M
J Clin Pharm Ther; 2020 Oct; 45(5):1172-1174. PubMed ID: 31985841
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Dabrafenib for three children with brainstem BRAF
Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
[TBL] [Abstract][Full Text] [Related]
13. Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF
Chic N; Mezquita L; Aldea M; Chebib R; Caramella C; Planchard D; Besse B
Clin Lung Cancer; 2021 Jan; 22(1):e54-e56. PubMed ID: 32896487
[No Abstract] [Full Text] [Related]
14. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
[TBL] [Abstract][Full Text] [Related]
17. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
20. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.
Spain L; Julve M; Larkin J
Expert Opin Pharmacother; 2016; 17(7):1031-8. PubMed ID: 27027150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
